333 related articles for article (PubMed ID: 19147430)
21. Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy.
Cimaz R; Meregalli E; Biggioggero M; Borghi O; Tincani A; Motta M; Airò P; Meroni PL
Toxicol Lett; 2004 Apr; 149(1-3):155-62. PubMed ID: 15093261
[TBL] [Abstract][Full Text] [Related]
22. [Immunosuppressive drugs in organ transplantations].
Di Mezza F
Minerva Chir; 1968 Mar; 23(5):212-29. PubMed ID: 4174995
[No Abstract] [Full Text] [Related]
23. Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants.
Biggioggero M; Borghi MO; Gerosa M; Trespidi L; Cimaz R; Meroni PI
Lupus; 2007; 16(8):651-6. PubMed ID: 17711903
[TBL] [Abstract][Full Text] [Related]
24. Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.
Bugelski PJ; Volk A; Walker MR; Krayer JH; Martin P; Descotes J
Int J Toxicol; 2010; 29(5):435-66. PubMed ID: 20884856
[TBL] [Abstract][Full Text] [Related]
25. Immunosuppressive drugs in dermatology--benefits and threats.
Kowal A; Warmińska J; Krasowska D
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):14-21. PubMed ID: 15323159
[TBL] [Abstract][Full Text] [Related]
26. [Drugs affecting apoptosis in the immune system].
Igaz P; Müzes G
Orv Hetil; 2001 Dec; 142(51):2829-33. PubMed ID: 11828931
[TBL] [Abstract][Full Text] [Related]
27. [Mechanism of action and therapeutic use of cyclosporin A. Experimental and clinical experiences in dermatology].
Laub R
Dermatol Monatsschr; 1990; 176(5-6):281-91. PubMed ID: 2227046
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive therapy.
Katz P
Am Fam Physician; 1983 Dec; 28(6):172-9. PubMed ID: 6650334
[No Abstract] [Full Text] [Related]
29. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists.
Stahn C; Löwenberg M; Hommes DW; Buttgereit F
Mol Cell Endocrinol; 2007 Sep; 275(1-2):71-8. PubMed ID: 17630118
[TBL] [Abstract][Full Text] [Related]
30. Immunomodulatory drugs and their application to the management of canine immune-mediated disease.
Whitley NT; Day MJ
J Small Anim Pract; 2011 Feb; 52(2):70-85. PubMed ID: 21265846
[TBL] [Abstract][Full Text] [Related]
31. [Treatment with tacrolimus in autoimmune diseases].
Sádaba B; Azanza JR; García Quetglas E; Fernández V
Rev Med Univ Navarra; 2004; 48(3):24-38. PubMed ID: 15622922
[TBL] [Abstract][Full Text] [Related]
32. Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine.
Hirano T
Int Immunopharmacol; 2007 Jan; 7(1):3-22. PubMed ID: 17161812
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effect of Cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome.
Liu X; Yang P; Lin X; Ren X; Zhou H; Huang X; Chi W; Kijlstra A; Chen L
Clin Immunol; 2009 May; 131(2):333-42. PubMed ID: 19200788
[TBL] [Abstract][Full Text] [Related]
34. Current and future treatments of autoimmune hepatitis.
Czaja AJ
Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):269-91. PubMed ID: 19485809
[TBL] [Abstract][Full Text] [Related]
35. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study.
Ekberg H; Mamelok RD; Pearson TC; Vincenti F; Tedesco-Silva H; Daloze P
Transplantation; 2009 May; 87(9):1360-6. PubMed ID: 19424036
[TBL] [Abstract][Full Text] [Related]
36. Immunosuppressive drugs: the first 50 years and a glance forward.
Allison AC
Immunopharmacology; 2000 May; 47(2-3):63-83. PubMed ID: 10878284
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppressants: cellular and molecular mechanisms of action.
Suthanthiran M; Morris RE; Strom TB
Am J Kidney Dis; 1996 Aug; 28(2):159-72. PubMed ID: 8768909
[TBL] [Abstract][Full Text] [Related]
38. Systemic therapeutic options for severe atopic dermatitis.
BuBmann C; Bieber T; Novak N
J Dtsch Dermatol Ges; 2009 Mar; 7(3):205-19. PubMed ID: 18759739
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of action of new immunosuppressive drugs.
Morris RE
Ther Drug Monit; 1995 Dec; 17(6):564-9. PubMed ID: 8588221
[TBL] [Abstract][Full Text] [Related]
40. Research in practice: Treatment of autoimmune bullous disorders.
Hertl M
J Dtsch Dermatol Ges; 2009 Jun; 7(6):500-5. PubMed ID: 19243480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
